Is Quoin Pharmaceuticals Stock a Good Investment?
Quoin Pharmaceuticals Investment Advice | QNRX |
- Examine Quoin Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Quoin Pharmaceuticals' leadership team and their track record. Good management can help Quoin Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Quoin Pharmaceuticals' business and its evolving consumer preferences.
- Compare Quoin Pharmaceuticals' performance and market position to its competitors. Analyze how Quoin Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Quoin Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Quoin Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Quoin Pharmaceuticals Ltd stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Quoin Pharmaceuticals Ltd is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Quoin Pharmaceuticals Stock
Researching Quoin Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 0.63. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Quoin Pharmaceuticals recorded a loss per share of 2.0. The entity last dividend was issued on the 23rd of October 2019. The firm had 1:12 split on the 18th of July 2023.
To determine if Quoin Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Quoin Pharmaceuticals' research are outlined below:
| Quoin Pharmaceuticals generated a negative expected return over the last 90 days | |
| Quoin Pharmaceuticals has high historical volatility and very poor performance | |
| Quoin Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Quoin Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Quoin Pharmaceuticals Ltd currently holds 6.5 B in liabilities with Debt to Equity (D/E) ratio of 0.47, which is about average as compared to similar companies. Quoin Pharmaceuticals has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Quoin Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (8.96 B) with profit before overhead, payroll, taxes, and interest of 0. | |
| Quoin Pharmaceuticals Ltd currently holds about 2.69 M in cash with (7.86 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.56, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from simplywall.st: Improved Revenues Required Before Hvsen Biotechnology Co., Ltd. Stocks 30 percent Jump Looks Justified |
Quoin Pharmaceuticals Quarterly Cash And Short Term Investments |
|
Quoin Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Quoin Pharmaceuticals Ltd. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Quoin Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Quoin Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Quoin Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-08 | 2023-03-31 | -0.28 | -0.34 | -0.06 | 21 | ||
2025-03-11 | 2024-12-31 | -0.43 | -0.2781 | 0.1519 | 35 | ||
2023-03-08 | 2022-12-31 | -0.62 | -0.41 | 0.21 | 33 | ||
2024-08-08 | 2024-06-30 | -0.61 | -0.39 | 0.22 | 36 | ||
2024-05-09 | 2024-03-31 | -0.76 | -1.11 | -0.35 | 46 | ||
2022-11-10 | 2022-09-30 | -1.35 | -0.94 | 0.41 | 30 | ||
2023-08-02 | 2023-06-30 | -2.82 | -2.13 | 0.69 | 24 | ||
2023-11-08 | 2023-09-30 | -2.72 | -1.95 | 0.77 | 28 |
Know Quoin Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Quoin Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Quoin Pharmaceuticals Ltd backward and forwards among themselves. Quoin Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Quoin Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-12-31 | 4.8 K | Sbi Securities Co Ltd | 2024-12-31 | 24.0 | Raiffeisen Bank International Ag | 2024-12-31 | 17.0 | Resources Investment Advisors Inc | 2024-09-30 | 0.0 | Susquehanna International Group, Llp | 2024-09-30 | 0.0 | Jpmorgan Chase & Co | 2024-12-31 | 0.0 | Two Sigma Investments Llc | 2024-09-30 | 0.0 | Virtu Financial Llc | 2024-12-31 | 0.0 | Bank Of America Corp | 2024-09-30 | 0.0 | Armistice Capital, Llc | 2024-12-31 | 530 K | Altium Capital Management, Lp | 2024-12-31 | 282.2 K |
Quoin Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.07 M.Market Cap |
|
Quoin Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.59) | (0.56) | |
| Return On Capital Employed | (1.26) | (1.32) | |
| Return On Assets | (0.57) | (0.54) | |
| Return On Equity | (0.97) | (1.02) |
Determining Quoin Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Quoin Pharmaceuticals is a good buy. For example, gross profit margin measures Quoin Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Quoin Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Quoin Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Quoin Pharmaceuticals Ltd. Check Quoin Pharmaceuticals' Beneish M Score to see the likelihood of Quoin Pharmaceuticals' management manipulating its earnings.
Evaluate Quoin Pharmaceuticals' management efficiency
Quoin Pharmaceuticals has return on total asset (ROA) of (0.4272) % which means that it has lost $0.4272 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2056) %, meaning that it created substantial loss on money invested by shareholders. Quoin Pharmaceuticals' management efficiency ratios could be used to measure how well Quoin Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.56 in 2025. Return On Capital Employed is likely to drop to -1.32 in 2025. At this time, Quoin Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 822.5 M in 2025, despite the fact that Other Assets are likely to grow to (61.56).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2 K | 1.6 K | |
| Tangible Book Value Per Share | 1.9 K | 1.6 K | |
| Enterprise Value Over EBITDA | (0.25) | (0.26) | |
| Enterprise Value Multiple | (0.25) | (0.26) | |
| Enterprise Value | -3.6 B | -3.4 B |
The strategic initiatives led by Quoin Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 1.591 |
Basic technical analysis of Quoin Stock
As of the 27th of March, Quoin Pharmaceuticals holds the Coefficient Of Variation of (954.71), variance of 63.05, and Risk Adjusted Performance of (0.08). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Quoin Pharmaceuticals, as well as the relationship between them.Quoin Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Quoin Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Quoin Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Quoin Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Michael Myers over six months ago Acquisition by Michael Myers of 5322 shares of Quoin Pharmaceuticals at 0.6558 subject to Rule 16b-3 | ||
Michael Myers over six months ago Acquisition by Michael Myers of 800 shares of Quoin Pharmaceuticals at 0.619 subject to Rule 16b-3 | ||
Langer Dennis over six months ago Disposition of 297 shares by Langer Dennis of Quoin Pharmaceuticals at 0.732 subject to Rule 16b-3 | ||
Denise Carter over a year ago Acquisition by Denise Carter of 80966 shares of Quoin Pharmaceuticals subject to Rule 16b-3 | ||
Cooper Joseph Patrick over a year ago Quoin Pharmaceuticals exotic insider transaction detected |
Quoin Pharmaceuticals' Outstanding Corporate Bonds
Quoin Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Quoin Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Quoin bonds can be classified according to their maturity, which is the date when Quoin Pharmaceuticals Ltd has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Quoin Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Quoin Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (2.46) | |||
| Mean Deviation | 5.39 | |||
| Coefficient Of Variation | (954.71) | |||
| Standard Deviation | 7.94 | |||
| Variance | 63.05 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.84) | |||
| Total Risk Alpha | (0.82) | |||
| Treynor Ratio | (2.47) | |||
| Maximum Drawdown | 57.78 | |||
| Value At Risk | (10.53) | |||
| Potential Upside | 14.29 | |||
| Skewness | 0.2086 | |||
| Kurtosis | 4.31 |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (2.46) | |||
| Mean Deviation | 5.39 | |||
| Coefficient Of Variation | (954.71) | |||
| Standard Deviation | 7.94 | |||
| Variance | 63.05 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.84) | |||
| Total Risk Alpha | (0.82) | |||
| Treynor Ratio | (2.47) | |||
| Maximum Drawdown | 57.78 | |||
| Value At Risk | (10.53) | |||
| Potential Upside | 14.29 | |||
| Skewness | 0.2086 | |||
| Kurtosis | 4.31 |
Consider Quoin Pharmaceuticals' intraday indicators
Quoin Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Quoin Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Quoin Pharmaceuticals time-series forecasting models is one of many Quoin Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Quoin Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Quoin Stock media impact
Far too much social signal, news, headlines, and media speculation about Quoin Pharmaceuticals that are available to investors today. That information is available publicly through Quoin media outlets and privately through word of mouth or via Quoin internal channels. However, regardless of the origin, that massive amount of Quoin data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Quoin Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Quoin Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Quoin Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Quoin Pharmaceuticals alpha.
Quoin Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Quoin Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Additional Tools for Quoin Stock Analysis
When running Quoin Pharmaceuticals' price analysis, check to measure Quoin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quoin Pharmaceuticals is operating at the current time. Most of Quoin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Quoin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quoin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Quoin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.